


Curriculum Vitae

Name	Alexander Swarbrick	
Current Position & Affiliation	Principal Research Fellow & Laboratory Head, Garvan Institute of Medical Research Petre Foundation Chair of Breast Cancer Research Conjoint Associate Professor, UNSW, Sydney	
Country	Australia	

Educational Background

- 1995 1st class Honours, Molecular & Cellular Biology, UNSW Sydney
- 2003 Doctorate of Philosophy, UNSW Sydney

Professional Experience

AWARDS AND RECOGNITION

- 2020: Petre Foundation Chair of Breast Cancer Research
- 2019: NHMRC Senior Research Fellowship
- 2013: NHMRC Career Development Fellowship II
- 2011: NSW Premier's award for Outstanding Research Fellow, Cancer Institute NSW
- 2009: CINSW Early Career Fellowship and NBCF Early Career Fellowship
- 2007: Sydney University Medal for Excellence in Medical Research
- 2005: CJ Martin Fellowship from the NHMRC

SERVICE TO THE INSTITUTE AND TO THE SCIENTIFIC DISCIPLINE

- Chair, Lorne Cancer Conference 2019 & 2020. >400 attendees
- Co-chair, Lorne Cancer Conference 2017 & 2018. >400 attendees
- Joint chair and founder, Australian Translational Breast Cancer Research Symposium 2016-current. >200 Attendees.
- Member, Oz Single Cell organising committee 2019-current
- Chair, Cancer Research Executive Committee, Cancer Council NSW
- Convenor of a 1.5hr workshop on multi-omic single cell methods for Oz Single Cell 2019.

Attended by ~ 100

- Member, Sydney Catalyst International Cancer Research Symposium 2017
- Member, Australian Breast Cancer Tissue Bank Scientific Advisory Committee 2015-current
- Chair, St Vincent's Campus Institutional Biosafety Committee. 2012-current
- Chair, Garvan Institute Faculty Retreat Committee. 2015

Professional Organizations

- Associate Editor for Breast Cancer Research in the areas of cellular and molecular pathogenesis. 2020-current
- Member of grant review committee for Cancer Australia 2021
- External assessor for ~ 7 applications/year for NHMRC project grants (2008-current), as well as other bodies including Cancer Institute NSW, Cancer Research UK, Sparks UK and the UK MRC.
- GRP (Oncology) for the NHMRC in 2011, 2014, 2017.
- Grant review committee for the Victorian Cancer Agency's startup fund, 2013
- National Breast Cancer Grant Committee, 2012, 2013, 2017, 2019
- Sydney Catalyst Grant review panel, 2016, 2017, 2019
- Regular Ad hoc reviewer for journals including Nature Communications, Nature Genetics, Cell Reports, Nature Biotechnology, Breast Cancer Research, Cancer Research, Oncogene, Cell Genomics, Nature, e-Life, Nucleic acids Research.

Main Scientific Publications

1. Wu, S. Z., D. Roden, *et. al.*, E. Lim, S. X. Liu and A. Swarbrick "Stromal cell diversity associated with immune evasion in human triple-negative breast cancer" EMBO Journal *In Press*
2. Singh, M., G. Al-Eryani, S. Carswell, J. M. Ferguson, J. Blackburn, K. Barton, D. Roden, F. Luciani, T. Giang Phan, S. Junankar, K. Jackson, C. C. Goodnow, M. A. Smith and A. Swarbrick (2019). "High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes." Nat Commun **10**(1): 3120.
3. Cazet, A. S., M. N. Hui, B. L. Elsworth, S. Z. Wu, D. Roden, C. L. Chan, J. N. Skhinas, R. Collot, J. Yang, K. Harvey, M. Z. Johan, C. Cooper, R. Nair, D. Herrmann, A. McFarland, N. Deng, M. Ruiz-Borrego, F. Rojo, J. M. Trigo, S. Bezares, R. Caballero, E. Lim, P. Timpson, S. O'Toole, D. N. Watkins, T. R. Cox, M. S. Samuel, M. Martin and A. Swarbrick (2018). "Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer." Nature Communications **9**(1): 2897.

4. Hickey, T. E., L. A. Selth, et. al. A. Swarbrick, E. Lim, J. S. Carroll and W. D. Tilley. "The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer." Nature Medicine In Press
 5. Junankar, S., B. L., D. L. Roden, R. Nair, B. Elsworth, D. Gallego-Ortega, P. Lacaze, A. Cazet, I. Nikolic, W. Siang-Teo, J. Yang, A. McFarland, K. Harvey, M. J. Naylor, S. R. Lakhani, P. T. Simpson, A. Raghavendra, J. Saunus, J. Madore, W. Kaplan, C. Ormandy, E. K. A. Millar, S. O'Toole, K. Yun and A. Swarbrick (2015). "ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype " Nature Communications **6**: 6548.
 6. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Belloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. *Nat Medicine*, 16:1134-1140, doi:10.1038/nm.2227 (2010).
 7. Swarbrick A, Roy E, Allen T, Bishop JM. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. *PNAS*, 105:5402-5407, doi:10.1073/pnas.0801505105 (2008).
-